Short answer: Dose uniformity is a product-specific acceptance decision. Buyers should agree on the ingredient to measure, the unit sampling plan, the analytical method and the release rule before approving a pilot batch.
Why a uniform sheet may still yield variable strips
A finished strip has to deliver the amount stated for that product. A smooth-looking sheet cannot establish that result. Variation can enter through ingredient distribution, changes across the width of a coated web, drying differences or the way the web is converted into units. The relevant measure is therefore taken on individual finished strips, not only on a pooled sheet sample. The test plan should reflect the ingredient and product classification.
A buyer evaluating vitamin films should distinguish a declared active from a flavor or color marker. If several actives are present, the specification needs to state which are tested at release and why. The manufacturing partner should explain what in-process observations support the final unit test.
A practical specification request
- Identity and target amount for each declared active per strip
- Unit dimensions, mass and acceptable visual defects
- Sampling positions and number of finished units
- Validated or appropriately qualified assay method
- Acceptance criteria, retest rules and batch disposition owner
Connect the unit result to the release decision
For a US dietary supplement project, FDA’s 21 CFR Part 111 framework calls for specifications, quality control and records that match the product. A certificate of analysis is useful only when its method, limits and actual results can be interpreted against the agreed specification. The buyer should ask for a representative anonymized batch record or release package during supplier qualification, then agree on the exact documents for commercial lots.
Disintegration is a separate performance question. USP chapter <1711> discusses approaches to performance testing for oral dosage forms not covered by other chapters. Its existence does not assign a universal disintegration limit to every supplement film. Method and limit must be justified for the actual formulation and use.
Questions to ask before the first commercial run
- Which strip-level result triggers investigation?
- How are edge and center web positions represented?
- Who reviews out-of-trend results and approves release?
- Will the same method be used after a formulation or site change?
Buyer questions
Is film thickness enough to prove dose uniformity?
No. Thickness can be informative, but finished-unit assay is needed when it is the agreed measure of active content.
Can one acceptance range apply to every oral film?
No. The product classification, ingredient, method and applicable requirements determine the acceptance criteria.
What should a batch document show?
It should connect lot identity, sampling, test method, actual results, deviations and the release decision.
References and further reading
Last reviewed: . Project parameters remain subject to formula, packaging and target-market review.